Ron Vergona

1.3k total citations
17 papers, 734 citations indexed

About

Ron Vergona is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Oncology. According to data from OpenAlex, Ron Vergona has authored 17 papers receiving a total of 734 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Cardiology and Cardiovascular Medicine and 4 papers in Oncology. Recurrent topics in Ron Vergona's work include Ovarian cancer diagnosis and treatment (4 papers), Blood Coagulation and Thrombosis Mechanisms (3 papers) and Cancer Risks and Factors (2 papers). Ron Vergona is often cited by papers focused on Ovarian cancer diagnosis and treatment (4 papers), Blood Coagulation and Thrombosis Mechanisms (3 papers) and Cancer Risks and Factors (2 papers). Ron Vergona collaborates with scholars based in United States and Israel. Ron Vergona's co-authors include Jeane Ann Grisso, Jennifer Klapper, Mark A. Morgan, Roberta B. Ness, James E. Wheeler, Carrie M. Cottreau, James J. Schlesselman, Mark Sullivan, Katalin Kauser and Meredith Halks‐Miller and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Pharmacology and Experimental Therapeutics and American Journal of Physiology-Heart and Circulatory Physiology.

In The Last Decade

Ron Vergona

17 papers receiving 702 citations

Peers

Countries citing papers authored by Ron Vergona

Since Specialization

Citations

This map shows the geographic impact of Ron Vergona's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ron Vergona with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ron Vergona more than expected).

Fields of papers citing papers by Ron Vergona

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ron Vergona. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ron Vergona. The network helps show where Ron Vergona may publish in the future.

Co-authorship network of co-authors of Ron Vergona

This figure shows the co-authorship network connecting the top 25 collaborators of Ron Vergona. A scholar is included among the top collaborators of Ron Vergona based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ron Vergona. Ron Vergona is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): Pharmacodynamic and pharmacokinetic characterization 2008 ·Thrombosis Research ·Joseph Post, (unknown), Yixin Wang, Jon Vincelette, Ron Vergona, (unknown), Judi Bryant, Mark Sullivan, William P. Dole, John Morser, Babu Subramanyam	27
2	Overexpression of PAI-1 prevents the development of abdominal aortic aneurysm in mice 2007 ·Gene Therapy ·Hu Sheng Qian, (unknown), Perry Liu, Katalin Kauser, Meredith Halks‐Miller, Ron Vergona, Mark Sullivan, William P. Dole, (unknown)	39
3	3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa) 2006 ·Bioorganic & Medicinal Chemistry Letters ·Imadul Islam, Judi Bryant, Karen May, Raju Mohan, Shendong Yuan, (unknown), John Morser, Lei Zhao, Ron Vergona, Kathy White, Marc Adler, Marc Whitlow, Brad O. Buckman	25
4	Effective treatment of vascular endothelial growth factor refractory hindlimb ischemia by a mutant endothelial nitric oxide synthase gene 2006 ·Gene Therapy ·Hu Sheng Qian, Perry Liu, (unknown), Ann E. Orme, Meredith Halks‐Miller, Steven M. Hill, Faguang Jin, Peter J. Kretschmer, Eric Blasko, Linda Cashion, Paul Szymanski, Ron Vergona, Richard N. Harkins, Jin Yu, William C. Sessa, William P. Dole, Gabor M. Rubanyi, Katalin Kauser	15
5	Maternal and fetal amino acid concentrations and fetal outcomes during pre-eclampsia 2003 ·Reproduction ·(unknown), (unknown), R. B. Ness, (unknown), A. Daftary, (unknown), Ron Vergona, David N. Finegold	41
6	Design, Synthesis, and Biological Activity of Novel Factor Xa Inhibitors: 4-Aryloxy Substituents of 2,6-Diphenoxypyridines††See ref. 1. 2002 ·Bioorganic & Medicinal Chemistry ·Howard P. Ng, Brad O. Buckman, Keith Eagen, William J. Guilford, Monica J. Kochanny, Raju Mohan, Kenneth J. Shaw, Shung Wu, Dao Lentz, Amy Liang, Lan Trinh, Elena Ho, David F. Smith, Babu Subramanyam, Ron Vergona, (unknown), Kathy White, Mark Sullivan, Michael M. Morrissey, Gary B. Phillips	6
7	Oral Contraceptives, Other Methods of Contraception, and Risk Reduction for Ovarian Cancer 2001 ·Epidemiology ·Roberta B. Ness, Jeane Ann Grisso, Ron Vergona, Jennifer Klapper, Mark A. Morgan, James E. Wheeler	42
8	Risk of Ovarian Cancer in Relation to Estrogen and Progestin Dose and Use Characteristics of Oral Contraceptives 2001 ·Obstetrical & Gynecological Survey ·Roberta B. Ness, Jeane Ann Grisso, Jennifer Klapper, James J. Schlesselman, Stacey B. Silberzweig, Ron Vergona, Mark A. Morgan, James E. Wheeler	1
9	Identification of Selective Estrogen Receptor Modulators by Their Gene Expression Fingerprints 2000 ·Journal of Biological Chemistry ·Deborah A. Zajchowski, Katalin Kauser, Daguang Zhu, Lynn Webster, (unknown), Frank A. White, (unknown), (unknown), (unknown), Phyllis Ponte, Christa Hegele‐Hartung, R. Knauthe, Karl‐Heinrich Fritzemeier, Ron Vergona, Gabor M. Rubanyi	33
10	Factors Related to Inflammation of the Ovarian Epithelium and Risk of Ovarian Cancer 2000 ·Epidemiology ·Roberta B. Ness, Jeane Ann Grisso, Carrie M. Cottreau, Jennifer Klapper, Ron Vergona, James E. Wheeler, Mark A. Morgan, James J. Schlesselman	281
11	Increased aortic stiffness assessed by pulse wave velocity in apolipoprotein E-deficient mice 2000 ·American Journal of Physiology-Heart and Circulatory Physiology ·Yixin Wang, Meredith Halks‐Miller, Ron Vergona, Mark Sullivan, Richard M. Fitch, Cornell Mallari, Baby Martin-McNulty, Valdeci da Cunha, Ana D. Freay, Gabor M. Rubanyi, Katalin Kauser	96
12	Effects of ZK-807834, a Novel Inhibitor of Factor Xa, on Arterial and Venous Thrombosis in Rabbits 2000 ·Journal of Cardiovascular Pharmacology ·Dana R. Abendschein, (unknown), Daniel Martín, Ron Vergona, Joseph Post, Galina Rumennik, Mark Sullivan, Paul R. Eisenberg, David R. Light	26
13	Racial differences in ovarian cancer risk. 2000 ·PubMed ·R. B. Ness, Jeane Ann Grisso, Jennifer Klapper, Ron Vergona	31
14	Immune responses to killed influenza vaccine in patients with type 1 diabetes: altered responses associated with HLA-DR 3 and DR 4. 1988 ·PubMed ·(unknown), Philip Fireman, R. E. LaPorte, (unknown), (unknown), Ron Vergona	11
15	ACTH 1–24-induced potentiation of norepinephrine contractile responses in aortic strips from spontaneously hypertensive (SH) and normotensive (WKY) rats 1985 ·Peptides ·Ron Vergona, Fleur L. Strand, Misha Cohen	1
16	The cardiovascular and autonomic properties of N-phenylpiperazine (NPP) in several animal models. 1982 ·Journal of Pharmacology and Experimental Therapeutics ·Misha Cohen, Elvira Hinsch, (unknown), Ron Vergona, (unknown), (unknown)	12
17	A comparative diuretic and tissue distribution study of bumetanide and furosemide in the dog. 1976 ·Journal of Pharmacology and Experimental Therapeutics ·Mazal Cohen, Elvira Hinsch, Ron Vergona, (unknown), Stanley J. Kolis, Morton A. Schwartz	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact